Bayer HealthCare Pharmaceuticals today confirmed that results of a Phase II trial were published in the July 1 edition of the Journal of Clinical Oncology. The study showed that Leukine(R) (sargramostim) demonstrated a median overall survival of 65 months and increased mature dendritic cells in high-risk melanoma patients. Dendritic cells are special antigen-presenting cells that [...]

Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug Administration (FDA) has approved ACIPHEX (rabeprazole sodium) 20 mg for the short-term (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in adolescents ages 12 and above.
Included in the submission was a 12-week, multi-center, [...]